CENTESSA PHARMACEUTICALS-ADR (CNTA)

US1523091007 - ADR

17.945  +1.21 (+7.2%)

Fundamental Rating

2

Overall CNTA gets a fundamental rating of 2 out of 10. We evaluated CNTA against 565 industry peers in the Biotechnology industry. While CNTA seems to be doing ok healthwise, there are quite some concerns on its profitability. CNTA does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

CNTA had negative earnings in the past year.
In the past year CNTA has reported a negative cash flow from operations.
In the past 5 years CNTA always reported negative net income.
CNTA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

CNTA has a Return On Assets (-41.94%) which is comparable to the rest of the industry.
The Return On Equity of CNTA (-63.95%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -41.94%
ROE -63.95%
ROIC N/A
ROA(3y)-50.38%
ROA(5y)-53.58%
ROE(3y)-68.59%
ROE(5y)-117.32%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CNTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

CNTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CNTA has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, CNTA has a worse debt to assets ratio.

2.2 Solvency

CNTA has an Altman-Z score of 6.86. This indicates that CNTA is financially healthy and has little risk of bankruptcy at the moment.
CNTA has a Altman-Z score of 6.86. This is amongst the best in the industry. CNTA outperforms 82.53% of its industry peers.
CNTA has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.32, CNTA is not doing good in the industry: 70.77% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z 6.86
ROIC/WACCN/A
WACC8.9%

2.3 Liquidity

A Current Ratio of 8.00 indicates that CNTA has no problem at all paying its short term obligations.
With a decent Current ratio value of 8.00, CNTA is doing good in the industry, outperforming 73.62% of the companies in the same industry.
CNTA has a Quick Ratio of 8.00. This indicates that CNTA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.00, CNTA is doing good in the industry, outperforming 74.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8
Quick Ratio 8

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.81% over the past year.
EPS 1Y (TTM)13.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CNTA will show a small growth in Earnings Per Share. The EPS will grow by 7.68% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.16%
EPS Next 2Y-5.36%
EPS Next 3Y-3.35%
EPS Next 5Y7.68%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CNTA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CNTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CNTA's earnings are expected to decrease with -3.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.36%
EPS Next 3Y-3.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CNTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CENTESSA PHARMACEUTICALS-ADR

NASDAQ:CNTA (11/21/2024, 2:26:03 PM)

17.945

+1.21 (+7.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.31B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.94%
ROE -63.95%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 8
Quick Ratio 8
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)13.81%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-6.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y